Cargando…

Surgical treatment of small-sized non-small cell lung cancer—a dilemma for surgeons

Detalles Bibliográficos
Autores principales:	Kodama, Ken, Takeda, Masashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656331/ https://www.ncbi.nlm.nih.gov/pubmed/33209442 http://dx.doi.org/10.21037/jtd-20-1651

Ejemplares similares

EGFR and non-small cell lung cancer: implications for surgical practice
por: Varela, Gonzalo, et al.
Publicado: (2020)

Surgical resection of advanced non-small cell lung cancer after a response to EGFR-TKI: presentation of two cases and a literature review
por: Yamamoto, Yoko, et al.
Publicado: (2017)

Radical segmentectomy as a potential alternative surgical treatment with curative intent in early-stage non-small cell lung cancer
por: Koike, Terumoto, et al.
Publicado: (2020)

Implications of the success of EGFR-targeted therapy in advanced non–small cell lung cancer for its application to the adjuvant setting
por: Takeda, Masayuki
Publicado: (2020)

Surgery for stage IV non-small cell lung cancer?
por: Puig, Carlos A., et al.
Publicado: (2020)

Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR?
por: Tanzawa, Shigeru, et al.
Publicado: (2019)

Commentary: Segmentectomy as a standard surgery, a new era in small sized, peripheral, non–small cell lung cancer
por: Mimae, Takahiro, et al.
Publicado: (2022)

Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC)
por: Yellala, Amulya, et al.
Publicado: (2020)

Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy?
por: Kanemura, Hiroaki, et al.
Publicado: (2020)

Telisotuzumab vedotin with erlotinib in the treatment of non-small cell lung cancer: a well MET combination?
por: Kujtan, Lara, et al.
Publicado: (2023)

Proton stereotactic body radiation therapy for non-small cell lung cancer
por: Diwanji, Tejan, et al.
Publicado: (2020)

Anti-PDL1 effect in squamous non-small cell lung cancer
por: Rahouma, Mohamed, et al.
Publicado: (2020)

Postoperative management for non-small cell lung cancer harboring EGFR mutations
por: Tanaka, Fumihiro, et al.
Publicado: (2020)

Optimizing adjuvant therapy in EGFR-mutated non-small cell lung cancer
por: Shepherd, Annemarie F., et al.
Publicado: (2020)

Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer
por: Miura, Yosuke, et al.
Publicado: (2019)

Local treatment of synchronous oligometastatic non-small cell lung cancer (NSCLC)—current consensus and future perspectives
por: Almeldin, Doaa Said, et al.
Publicado: (2020)

Pembrolizumab in advanced non-small cell lung cancer: safety implications of dose adjustments
por: Gower, Arjan, et al.
Publicado: (2022)

Adjuvant treatment with EGFR TKI in resected non-small cell lung cancer with EGFR mutation: all that glitters is not gold!
por: Fiorelli, Alfonso, et al.
Publicado: (2020)

A reflection on the actual place of osimertinib in the treatment algorithm of EGFR-positive non-small cell lung cancer patients
por: Cortellini, Alessio, et al.
Publicado: (2020)

KEYNOTE-407: an effective and safe first-line treatment option for metastatic squamous non-small cell lung cancer
por: Chen, Hao, et al.
Publicado: (2023)

Dose matters for stereotactic body radiotherapy for early stage non-small cell lung cancer
por: Okoye, Christian C., et al.
Publicado: (2020)

Neoadjuvant immunotherapy with resectable non-small cell lung cancer: recent advances and future challenges
por: Ren, Sijia, et al.
Publicado: (2020)

Long-term benefit of immunotherapy in metastatic non-small cell lung cancer: the tale of the tail
por: Cali Daylan, Ayse Ece, et al.
Publicado: (2023)

Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?
por: Mienko, Fiona, et al.
Publicado: (2020)

Obesity Dilemma: Are There Enough Bariatric Surgeons?
por: Azizi, Fereidoun
Publicado: (2012)

First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer
por: Travert, Camille, et al.
Publicado: (2019)

Durvalumab plus novel agents in non-small cell lung cancer—a new COAST on the horizon?
por: Dempke, Wolfram C. M., et al.
Publicado: (2022)

Intracranial responses with selective KRAS-G12C inhibitors in non-small cell lung cancer
por: Lu, Kevin, et al.
Publicado: (2023)

Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?
por: Patel, Shruti R., et al.
Publicado: (2023)

First-line management of advanced non-small-cell lung cancer: can we do better?
por: Chouaïd, Christos, et al.
Publicado: (2023)

Targeting the adenosine 2A receptor in non-small cell lung cancer: shooting with blank bullets?
por: Garcia-Lorenzo, Esther, et al.
Publicado: (2023)

Surgery for early-stage small cell lung cancer: is it worth it?
por: Vyfhuis, Melissa A. L., et al.
Publicado: (2019)

New potential targeted strategies in small cell lung cancer
por: de Toro, María, et al.
Publicado: (2023)

Chemotherapy in non-small cell lung cancer: opportunities for advancement
por: Akhtari, Mani, et al.
Publicado: (2016)

Single-cell insights into the dynamic tumor microenvironment changes during immunotherapy of non-small cell lung cancer
por: Prazanowska, Karolina Hanna, et al.
Publicado: (2023)

Addition of atezolizumab to nab-paclitaxel plus carboplatin is a new standard option for the first-line treatment for non-squamous non-small cell lung cancer
por: Yamaguchi, Teppei, et al.
Publicado: (2019)

Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?
por: Travert, Camille, et al.
Publicado: (2020)

KEYNOTE-407: changing the way we treat stage IV squamous non-small cell lung cancer
por: Pacheco, Jose M.
Publicado: (2020)

Pembrolizumab plus platinum-based chemotherapy for squamous non-small cell lung cancer: the new kid on the block
por: Hockenhull, Kimberley, et al.
Publicado: (2021)

Neoadjuvant therapy in localized non-small cell lung cancer: can we do better than chemotherapy?
por: Chau, Brittney, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_j5vl2qbjp4b4305eekm7qu1aa3